SHIV virus-like particles bind and activate human dendritic cells

Zhang, Rongxin; Li, Min; Chen, Changyi; Yao, Qizhi

doi:10.1016/j.vaccine.2004.05.036

Cited by 26 publications

(25 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The apparent discordance of these results could be due to a different optimal timing for the sample collection and needs to be evaluated by more extensive observations. Nevertheless, the production of IFN-␥ by DCs induced with enveloped or nonenveloped VLP produced in different expression systems (prokaryotic, yeast, and baculovirus) is still a debated issue (18,28,30,49,53,54). In particular, Yang et al (53), reported that the CD8␣ ϩ…”

Section: Discussionmentioning

confidence: 99%

Baculovirus-Derived Human Immunodeficiency Virus Type 1 Virus-Like Particles Activate Dendritic Cells and Induce Ex Vivo T-Cell Responses

Buonaguro

Tornesello

Tagliamonte

et al. 2006

J Virol

114

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Baculovirus-Derived Human Immunodeficiency Virus Type 1 Virus-Like Particles Activate Dendritic Cells and Induce Ex Vivo T-Cell Responses

Buonaguro

Tornesello

Tagliamonte

et al. 2006

J Virol

114

View full text Add to dashboard Cite

“…Therefore, VLPs constitute a major advantage in the design of efficient and safe vaccines. In addition, VLPs have been shown to induce maturation of dendritic cells directly to enhance innate immune responses (29). VLPs are also potent inducers of B-cell responses and are capable of breaking self-tolerance (30).…”

Section: Introductionmentioning

confidence: 99%

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer

Bharadwaj

Zhang

et al. 2008

Molecular Cancer Therapeutics

142

159

View full text Add to dashboard Cite

Given the high fatality rate of pancreatic cancer, an effective treatment for this devastating disease is urgently needed. We have shown that mesothelin expression was higher in human pancreatic cancer cells than in human pancreatic duct epithelial cells, and mesothelin mRNA was substantially overexpressed in 18 of 21 (86%) clinical pancreatic adenocarcinoma specimens when compared with the surrounding normal tissues. However, the biological functions of mesothelin in tumor progression are not clearly understood. Here we studied the effects of mesothelin overexpression in pancreatic cancer cell proliferation and migration in vitro and pancreatic cancer progression in vivo. We found that forced expression of mesothelin significantly increased tumor cell proliferation and migration by 90% and 300%, respectively, and increased tumor volume by 4-fold in the nude mice xenograft model when compared with the vector control cell line. Silencing of mesothelin inhibited cell proliferation and migration in pancreatic cancer cells and ablated tumor progression in vivo. Vaccination with chimeric virus-like particles that contain human mesothelin substantially inhibited tumor progression in C57BL/6J mice. The increases in mesothelin-specific antibodies and CTL activity and the decrease in regulatory T cells correlated with reduced tumor progression and prolonged survival. This study revealed novel functions of mesothelin and suggested a new therapeutic vaccine strategy whereby mesothelin is targeted to control pancreatic cancer progression. [Mol Cancer Ther 2008;7(2):286 -96]

show abstract

“…When utilized as immunogens, HIV-1 and simian immunodeficiency virus (SIV) pseudovirions have been shown to induce both cellular and humoral immune responses in animal immunization protocols (9,10,31,46). Simian/human immunodeficiency virus pseudovirions have been shown to activate human dendritic cells in vivo, upregulating expression of cell surface activation markers and major histocompatibility complex molecules (52). However, the potential of purified HIV-1 pseudovirions bearing primary isolate envelope glycoproteins to elicit broadly cross-reactive neutralizing antibodies requires further investigation.…”

mentioning

confidence: 99%

Induction of Neutralizing Antibodies against Human Immunodeficiency Virus Type 1 Primary Isolates by Gag-Env Pseudovirion Immunization

Hammonds

Chen

Fouts

et al. 2005

J Virol

View full text Add to dashboard Cite

A major challenge for the development of an effective HIV vaccine is to elicit neutralizing antibodies against a broad array of primary isolates. Monomeric gp120-based vaccine approaches have not been successful in inducing this type of response, prompting a number of approaches designed to recreate the native glycoprotein complex that exists on the viral membrane. Gag-Env pseudovirions are noninfectious viruslike particles that recreate the native envelope glycoprotein structure and have the potential to generate neutralizing antibody responses against primary isolates. In this study, an inducible cell line was created in order to generate Gag-Env pseudovirions for examination of neutralizing antibody responses in guinea pigs. Unadjuvanted pseudovirions generated relatively weak anti-gp120 responses, while the use of a block copolymer water-in-oil emulsion or aluminum hydroxide combined with CpG oligodeoxynucleotides resulted in high levels of antibodies that bind to gp120. Sera from immunized animals neutralized a panel of human immunodeficiency virus (HIV) type 1 primary isolate viruses at titers that were significantly higher than that of the corresponding monomeric gp120 protein. Interpretation of these results was complicated by the occurrence of neutralizing antibodies directed against cellular (non-envelope protein) components of the pseudovirion. However, a major component of the pseudovirion-elicited antibody response was directed specifically against the HIV envelope. These results provide support for the role of pseudovirion-based vaccines in generating neutralizing antibodies against primary isolates of HIV and highlight the potential confounding role of antibodies directed at non-envelope cell surface components.

show abstract

SHIV virus-like particles bind and activate human dendritic cells

Cited by 26 publications

References 43 publications

Baculovirus-Derived Human Immunodeficiency Virus Type 1 Virus-Like Particles Activate Dendritic Cells and Induce Ex Vivo T-Cell Responses

Baculovirus-Derived Human Immunodeficiency Virus Type 1 Virus-Like Particles Activate Dendritic Cells and Induce Ex Vivo T-Cell Responses

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer

Induction of Neutralizing Antibodies against Human Immunodeficiency Virus Type 1 Primary Isolates by Gag-Env Pseudovirion Immunization

Contact Info

Product

Resources

About